PharmaLex begins new service line for compliance and quality services

Published: 16-May-2017
Regulatory Pharmaceutical

The merger with the compliance and quality specialist company, Complya, enables PharmaLex to build on its existing FDA expertise

The PharmaLex Group, specialist provider of development consulting and scientific affairs, regulatory affairs and pharmacovigilance, has completed the merger of Complya Consulting Group.

The merger enables PharmaLex to build on its existing US FDA Quality and Compliance expertise; Complya's main area of work is GXP Quality Assurance services.

The company also provide a spectrum of related consulting services, including GCP/GLP/GMP Quality Assurance and Regulatory Affairs support.

Following this acquisition, PharmaLex now has one the largest US pools of experts supporting pharmaceutical and biotech companies with their health authority obligations.

Tilo Netzer, CEO PharmaLex, said: “We can now provide the complete spectrum of services to support the requirements of health authorities in all mature markets – from regulatory strategy to quality assurance services.”

  • Companies:
  • PharmaLex
  • Complya
See more

You may also like

Regulatory

The right validation model: practical considerations and applications

Read more
It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Trending Articles

  1. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

The right validation model: practical considerations and applications

It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
Regulatory

European Commission adopts proposal to delay MDR deadlines

With thousands of outstanding conformity assessments for medical device certification under the Medical Device Regulation and limited capacity to manage these within the transition period, concerns about widespread product shortages in the EU market have been growing
Regulatory

Investment, outsourcing and globalisation: key trends for 2023

The start of 2023 has been challenging for the pharmaceutical industry. Economic constraints in Europe and the United States, staffing shortages, an increasingly complex regulatory environment and heightened competition for funding is putting pressure on companies
Regulatory

PharmaLex extends reach in Asia with Ascent merger

Headquartered in Tokyo, Ascent employs staff across Asia, and provides country-specific knowledge mixed with strategic advice from a global perspective
Regulatory

PharmaLex taps DocShifter for PDF generation

DocShifter is a document conversion and validation solution for pharmaceutical, biotech and medical device companies
Regulatory

Why Bayesian statistics is revolutionising pharmaceutical decision making

PharmaLex's Bruno Boulanger, Global Head of Statistics and Data Science, and Brad Carlin, Senior Adviser for Statistics and Data Science, explore the growing significance of Bayesian statistics in supporting decision-making across the development and regulatory processes and its potential to improve outcomes for the biopharmaceutical industry
Regulatory

EFSA declares titanium dioxide unsafe for food products

Thomas Eberwein, Head of Pharmaceutical Quality at Pharmalex, explains the EFSA’s recent decision to declare titanium dioxide unsafe for food products, and the implications for manufacturers
Subscribe now